AKRO
Akero Therapeutics Inc

2,217
Mkt Cap
$4.5B
Volume
60.00
52W High
$58.40
52W Low
$21.34
PE Ratio
-14.59
AKRO Fundamentals
Price
$54.69
Prev Close
$54.49
Open
$54.49
50D MA
$52.47
Beta
0.95
Avg. Volume
1.41M
EPS (Annual)
-$3.75
P/B
4.58
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Prudential Financial Inc. Purchases 48,055 Shares of Akero Therapeutics, Inc. $AKRO
Prudential Financial Inc. raised its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 125.0% in the 2nd quarter, according to the company in its most recent disclosure...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Loomis Sayles & Co. L P Acquires 51,850 Shares of Akero Therapeutics, Inc. $AKRO
Loomis Sayles & Co. L P raised its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 10.6% during the 2nd quarter, according to the company in its most recent filing with the...
MarketBeat·3d ago
News Placeholder
F m Investments LLC Has $960,000 Holdings in Akero Therapeutics, Inc. $AKRO
F m Investments LLC cut its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 37.1% during the 2nd quarter, according to the company in its most recent disclosure with the...
MarketBeat·3d ago
News Placeholder
7,107 Shares in Akero Therapeutics, Inc. $AKRO Bought by DLD Asset Management LP
DLD Asset Management LP bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·6d ago
News Placeholder
Foresite Capital Management VI LLC Has $13.07 Million Stock Holdings in Akero Therapeutics, Inc. $AKRO
Foresite Capital Management VI LLC lessened its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 32.9% during the 2nd quarter, according to its most recent filing with the...
MarketBeat·8d ago
News Placeholder
Ensign Peak Advisors Inc Has $10.05 Million Holdings in Akero Therapeutics, Inc. $AKRO
Ensign Peak Advisors Inc lifted its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 21.5% in the 2nd quarter, according to the company in its most recent filing with the SEC. The...
MarketBeat·10d ago
News Placeholder
Intech Investment Management LLC Sells 16,635 Shares of Akero Therapeutics, Inc. $AKRO
Intech Investment Management LLC lowered its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 28.4% in the second quarter, according to the company in its most recent...
MarketBeat·12d ago
News Placeholder
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to...
Business Wire·14d ago
News Placeholder
Bank of New York Mellon Corp Increases Stake in Akero Therapeutics, Inc. $AKRO
Bank of New York Mellon Corp increased its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 11.8% during the second quarter, according to its most recent Form 13F filing...
MarketBeat·15d ago
News Placeholder
Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss...
PR Newswire·16d ago

Latest AKRO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.